F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
End points of therapy in chronic hepatitis B.
TL;DR: Prevention of the progression of the disease to cirrhosis, decompensated cirrhotic disease, end-stage liver disease and hepatocellular carcinoma seems to be the best approach to improve survival.
Patent
Method for assaying replication of HBV and testing susceptibility to drugs
TL;DR: A method for measuring the replication capacity of HBV, e.g. in the presence of a pharmaceutical product, in particular an antiviral agent, was proposed in this paper.
Journal ArticleDOI
Gene Editing Technologies to Target HBV cccDNA
Maria Guadalupe Martinez,Elena M. Smekalova,Emmanuel Combe,Francine Gregoire,Fabien Zoulim,Barbara Testoni +5 more
TL;DR: In this paper , the authors discuss the latest developments and applications of gene editing and related approaches for directly targeting HBV DNA and, more specifically, covalently closed circular DNA (cccDNA) in infected hepatocytes.
Journal ArticleDOI
Retour d’expérience de deux CSAPA et enquête nationale sur la naloxone intranasale (Nalscue®) dans la prévention des overdoses aux opioïdes
Flavy Lenglard,Aurélie Berger-Vergiat,Delphine Ragonnet,Nathalie Duvernay,Philippe Lack,Emmanuel Poulet,Fabien Zoulim,Mathieu Chappuy +7 more
TL;DR: In this article, the authors present a survey on the caracteristiques des patients inclus dans ce dispositif au sein de deux centers and les results of l'enquete nationale sur la contribution des centres de soins, d'accompagnement et de prevention en addictologie (CSAPA) a ce nouvel outil de reduction des risques.
Journal ArticleDOI
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen — The ANRS CO20-CUPIC study
François Bailly,François Bailly,François Bailly,Victor Virlogeux,Victor Virlogeux,Cécilie Dufour,Pierre Pradat,Pierre Pradat,Pierre Pradat,Christophe Hézode,Dominique Larrey,Laurent Alric,Didier Samuel,Didier Samuel,Marc Bourlière,Sophie Metivier,Jean-Pierre Zarski,Hélène Fontaine,Véronique Loustaud-Ratti,Lawrence Serfaty,Jean-Pierre Bronowicki,Fabrice Carrat,Fabien Zoulim,Fabien Zoulim,Fabien Zoulim +24 more
TL;DR: The assessment of HCV RNA level after two weeks of triple therapy in cirrhotic non-responder patients is a good predictor of SVR and was useful to do an early diagnosis of viral breakthrough.